Zentalis Pharmaceuticals (ZNTL) Analyst & Key Data

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts4

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$3.51

Median Target+92.31%

$6.75

Potential upside vs current price

DCF Value-103.28%

-$0.12

Potential downside vs current price

Current Stock Price

$3.51

Median Target+92.31%

$6.75

Potential upside vs current price

DCF Value-103.28%

-$0.12

Potential downside vs current price

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts4

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$3.51

Median Target+92.31%

$6.75

Potential upside vs current price

DCF Value-103.28%

-$0.12

Potential downside vs current price

Current Stock Price

$3.51

Median Target+92.31%

$6.75

Potential upside vs current price

DCF Value-103.28%

-$0.12

Potential downside vs current price

Zentalis Pharmaceuticals, Inc.